Structured JSON API for this factor page: https://sharemaestro.com/factors/api/tickers/17bb16ae-0669-4cc3-a11b-3c5d9d18d48c/

NTLA

Intellia Therapeutics Inc
Chart
$13.54
Latest Week 2026-06-05
HealthcareBiotechnologySMALL
Snapshot 2026-06-07 · 0.0w · Fresh
0.18
OS Score
24.0%
Value
0.0%
Quality
88.0%
Momentum
2/9
F-Score
0.000
QV
StrategiesValueQualityMomentumCompositeInteractionsFactor AnalysisTrendsFundamentals
Strategy Eligibility
1 of 23 passing
★
OS Composite
✗
↗
Trending Value
✗
◆
Quality × Value
✗
🏛
Cornerstone Value
✗
🌿
Cornerstone Growth
✗
💎
Deep Value
✗
◇
VC2 Cheapest
✗
📐
EBITDA/EV
✗
◐
Veiled Value
✗
▣
Piotroski Bargains
✗
🔬
Quality Compounders
✗
📈
Consistent Earners
Noneyr
🌱
GARP
✗
🔄
Shareholder Yield
✗
💰
High Yield
✗
🚀
Momentum Leaders
✗
◉
Market Leaders
✗
◎
Tiny Titans
✗
🔍
Small Cap Value
✗
🛡
Low Volatility
✗
🏷
Sector Cheapest
✗
🧠
Capital Allocators
✗
⚡
Risk-Adj Momentum
✗
V
Value Analysis
Cheapness relative to fundamentals
24.0%ile
P/S
24.3×
P/B
2.6×
FCF Yield
-0.244
SH Yield
0.000
Relative Strength Across Value Dimensions
Multiples & Yields — Decomposition
VC1 (5-Factor)
78.00000000
/100 — 1=cheapest
VC2 (Trending Value)
86.00000000
/100
VC3 (Buyback)
86.00000000
/100
Negative FCF yield (-24.4%) — the business is currently cash-consumptive. VC2 score of 86.00000000/100 — expensive across all six composite measures.
Q
Quality Analysis
Profitability, efficiency, balance sheet & earnings quality
0.0%ile
ROE
-0.635
ROA
-0.520
Net Margin
-5.970
Op Margin
-6.168
GPA
-0.028
D/E
0.22
Current
6.10
F-Score
2/9
Quality Radar — Relative Strength
Profitability & Leverage Breakdown
Rev Growth
0.450
Stability
0.172
lower=better
Accruals
-0.041
lower=better
5yr Consist
Yes
Conservative balance sheet with D/E of 0.22. F-Score of 2/9 flags fundamental deterioration — multiple signals are weakening.
M
Momentum & Risk
Price trend, volatility regime, risk-adjusted returns
88.0%ile
6M Return
40.9%
12M Return
67.4%
12-1 Mom
74.2%
Risk-Adj
0.80
Vol 252d
93.1%
Vol 60d
225.5%
↑ Expanding
Max DD 12M
-67.9%
Return Comparison — 6M / 12M / 12-1
Volatility Regime — 60d vs 252d
12-1 momentum of 74% is very strong — a clear uptrend. Near-term vol (226%) is expanding vs long-term (93%) — risk is increasing.
OS
Composite & Factor Heatmap
All factors at a glance
0.18
Pillar Balance — Value / Quality / Momentum
Factor Heatmap — green=strong, red=weak
▦
Sector Context
Healthcare · 500 peers
Sector Value %ile
7.2%
Sector Quality %ile
0.2%
P/B z-score
-0.20
Sector Avg OS
63.3%
Ticker vs Sector Averages
Relative Valuation Z-Score
Top Sector Peers (By OS)
SymbolNameOSValueQualityMomentum
IRWD Ironwood Pharmaceuticals Inc 99.0% 93.0% 86.0% 98.0%
RIGL Rigel Pharmaceuticals Inc 98.0% 94.0% 92.0% 76.0%
FBIO Fortress Biotech Inc 98.0% 97.0% 93.0% 74.0%
CGEN Compugen 97.0% 90.0% 95.0% 76.0%
WW WW International, Inc. Common Stock 97.0% 88.0% 80.0% 99.0%
PBYI Puma Biotechnology Inc 97.0% 80.0% 97.0% 92.0%
FBIOP Fortress Biotech Inc Pref Series A 97.0% 81.0% 95.0% 90.0%
MD Mednax Inc 96.0% 87.0% 80.0% 87.0%
Factor Interactions
Hot but Volatile
Strong momentum (88th) but high volatility (93%). Momentum could reverse sharply.
Volatility Expanding
60-day vol (226%) significantly exceeds 252-day (93%). Near-term risk is elevated.
⚖
Factor Analysis
Comprehensive factor intelligence — strengths, weaknesses & cross-factor profile
Value
F
20.8% avg (4 factors)
Quality
D
33.9% avg (8 factors)
Momentum
A
83.4% avg (4 factors)
Risk
F
0.0% avg (1 factors)
Elevated risk profile — position sizing should reflect the higher volatility.
▲ Top Strengths — highest scoring factors
▼ Key Weaknesses — lowest scoring factors
Factor Persistence1 snapshots
FactorCurrentStreakTrendSpark
OS Composite0.180—1—
Value %ile0.240—1—
Quality %ile0.000—1—
Momentum %ile0.880—1—
F-Score2.000—1—
Confidence0.848—1—
Volatility0.931—1—
Value FactorsCheapness relative to fundamentals — lower multiples = cheaper
Price / Sales
24.27
Price / Book
2.58
FCF Yield
-24.4%
Sales Yield (1/P·S)
0.0444
Shareholder Yield
Div + net buyback / mktcap
0.0%
Quality FactorsProfitability, efficiency, and balance sheet strength
Return on Equity
-63.5%
Return on Assets
-52.0%
Net Margin
-597.0%
Operating Margin
-616.8%
Gross Profit / Assets
Novy-Marx GPA
-2.8%
Debt / Equity
0.22
Current Ratio
6.10
Accruals Ratio
(NI-OCF)/Assets — lower=better
-0.041
MomentumPrice trend strength over different horizons
6M Return
40.9%
12M Return
67.4%
12-1 Momentum
Jegadeesh-Titman (skip recent month)
74.2%
Risk-Adjusted Momentum
Mom 12-1 ÷ Vol
0.80
Growth & StabilityEarnings trajectory, consistency, and capital allocation
Revenue Growth (YoY)
45.0%
Earnings Stability (CV)
Lower = more stable
0.172
5yr Consistent
EPS up every year for 5 years
Yes
Piotroski F-Score
2
Dividend Yield
0.0%
Buyback Yield
0.0%
O'Shaughnessy CompositesValue Composites (WWOWS 4th Ed) — 1=cheapest, 100=most expensive
VC1 (5-factor)
P/E+P/S+P/B+P/CF+EBITDA/EV
78
VC2 (6-factor)
VC1 + Shareholder Yield — used for Trending Value
86
VC3 (6-factor)
VC1 + Buyback Yield — no dividend preference
86
Capital Allocation & AlphaAlpha within factors — quality of management decisions
Veiled Value
Expensive by P/B, cheap by everything else
No
Market Leader
Above-avg mcap+revenue, non-utility
No
All Stocks Universe
Market cap > $200M
Yes
Tiny Titan
Micro-cap, low P/S, positive momentum
No
Quarterly Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity
Annual Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity